4882 Stock Overview
Perseus Proteomics Inc., a drug discovery biotech venture company, develops antibody drugs against cancer and other diseases in Japan.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Perseus Proteomics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥315.00 |
| 52 Week High | JP¥879.00 |
| 52 Week Low | JP¥255.00 |
| Beta | 0.72 |
| 1 Month Change | -12.01% |
| 3 Month Change | -49.92% |
| 1 Year Change | 5.70% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -63.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4882 | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | 0% | -5.2% | -2.2% |
| 1Y | 5.7% | -30.4% | 29.7% |
Return vs Industry: 4882 exceeded the JP Biotechs industry which returned -30.4% over the past year.
Return vs Market: 4882 underperformed the JP Market which returned 29.7% over the past year.
Price Volatility
| 4882 volatility | |
|---|---|
| 4882 Average Weekly Movement | 12.2% |
| Biotechs Industry Average Movement | 7.9% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in JP Market | 8.3% |
| 10% least volatile stocks in JP Market | 2.2% |
Stable Share Price: 4882's share price has been volatile over the past 3 months.
Volatility Over Time: 4882's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 24 | Takuya Yokokawa | www.ppmx.com |
Perseus Proteomics Inc., a drug discovery biotech venture company, develops antibody drugs against cancer and other diseases in Japan. The company is involved in the antibody discovery activities; and antibody research support activities comprising hybridoma antibody sequencing, antibody protein production, and contract antibody research activities, as well as supply of antibody products. Its product pipeline includes PPMX-T001, an anti-hepatocarcinoma antibody; PPMX-T002, an anticancer drug; PPMX-T003, a drug for the treatment of adult T-cell; and PPMX-T004, an antibody drug conjugate.
Perseus Proteomics Inc. Fundamentals Summary
| 4882 fundamental statistics | |
|---|---|
| Market cap | JP¥3.67b |
| Earnings (TTM) | -JP¥1.12b |
| Revenue (TTM) | JP¥96.00m |
38.8x
P/S Ratio-3.3x
P/E RatioIs 4882 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4882 income statement (TTM) | |
|---|---|
| Revenue | JP¥96.00m |
| Cost of Revenue | JP¥10.00m |
| Gross Profit | JP¥86.00m |
| Other Expenses | JP¥1.21b |
| Earnings | -JP¥1.12b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 15, 2024
| Earnings per share (EPS) | -94.93 |
| Gross Margin | 89.58% |
| Net Profit Margin | -1,169.79% |
| Debt/Equity Ratio | 0% |
How did 4882 perform over the long term?
See historical performance and comparison